Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant staphylococcus aureus vaccine
- Development stage
- Phase 3
- Lead developer
- Olymvax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The Recombinant Staphylococcus Aureus Vaccine (Escherichia coli) is a biologic subunit vaccine candidate developed by Chongqing Yuanlun Biotechnology in collaboration with the Third Military Medical University (PLA, China). The vaccine is produced using recombinant protein expression technology within an *Escherichia coli* host system. It is designed to elicit a protective immune response against *Staphylococcus aureus* by targeting multiple key virulence factors and surface antigens, such as alpha-hemolysin (Hla) and iron-regulated surface determinant B (IsdB). The primary clinical focus is the prevention of postoperative *S. aureus* infections in adult patients undergoing elective orthopedic surgeries, such as closed fracture repairs. The program has progressed to Phase III clinical trials in China to evaluate its protective efficacy, safety, and immunogenicity.
- Other names
- Recombinant Staphylococcus aureus Vaccine (Escherichia coli)重组金黄色葡萄球菌疫苗(大肠杆菌)rSA vaccine
02
Targets
Hla (Staphylococcus aureus alpha toxin)IsdB (Iron surface determinant B)MntC (Staphylococcus aureus manganese transport protein C)SEB (Staphylococcal enterotoxin B)
Beyond the preview
Go deeper on recombinant staphylococcus aureus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant staphylococcus aureus vaccine.